Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Dec;74(23):11115-20.
doi: 10.1128/jvi.74.23.11115-11120.2000.

Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines

Affiliations

Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines

L Yoo et al. J Virol. 2000 Dec.

Abstract

Epstein-Barr virus (EBV) nuclear antigen (EBNA) 2 (EBNA2) is involved in upregulating the expression of both EBNAs and latency-associated membrane proteins. Transcription of the six EBNA genes, which are expressed in EBV-immortalized primary B cells, arises from one of two promoters, Cp and Wp, located near the left end of the viral genome. Wp is exclusively used to drive EBNA gene transcription during the initial stages of infection in primary B cells; induction of transcription from Cp follows. We previously have mapped an EBNA2-dependent enhancer upstream of Cp (M. Woisetschlaeger et al., Proc. Natl. Acad. Sci. USA 88:3942-3946, 1991) and, more recently, have demonstrated that deletion of this enhancer results in EBV-immortalized lymphoblastoid cell lines (LCLs) that are heavily biased toward the use of Wp to drive transcription of the EBNA genes (L. Yoo et al., J. Virol. 71:9134-9142, 1997). To assess the immortalizing capacity of this mutant EBV and to monitor the early events after infection of primary B cells, B cells isolated from cottontop marmosets were used to generate LCLs immortalized with the Cp EBNA2 enhancer deletion mutant virus. As previously reported, all EBV-infected marmoset LCLs examined could be triggered to produce significant levels of virus. Infection of human B cells with wild-type or Cp EBNA2 enhancer mutant viruses recovered from marmoset B-cell lines demonstrated that (i) the Cp EBNA2 enhancer mutant virus immortalizes primary human B cells nearly as efficiently as wild-type virus and (ii) the Cp EBNA2-dependent enhancer plays an important role in the induction of Cp activity during the early stages of infection. The latter is consistent with the phenotype of LCLs immortalized with the Cp EBNA2 enhancer mutant EBV. Finally, using an established LCL in which EBNA2 function is regulated by beta-estradiol, we showed that the loss of EBNA2 function results in an approximately 4-fold decrease in the steady-state levels of Cp-initiated transcripts and a concomitant increase in the steady-state levels of Wp-initiated transcripts. Taken together, these results provide strong evidence that EBNA2 plays an important role in regulating Cp activity. These results also demonstrate that diminished induction of Cp activity does not appear to affect the ability of EBV to immortalize primary B cells in cultures. Finally, as shown here, infection of marmoset B cells with immortalization-competent mutants of EBV provides a convenient reservoir for the production of mutant viruses.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
(A) Schematic diagram of the linearized EBV genome. EBNA open reading frames are indicated as gray arrows. The functions of the various EBNAs for regulating viral promoter activity are indicated with plus and minus signs. Viral transcription programs during type I, II, and III latencies are indicated below the genome diagram. TR, terminal repeat; IR, internal repeat; Qp, Q promoter. (B) Diagram of regulatory regions controlling Cp and Wp activities. The top diagram shows wild-type viral DNA sequences. oriP, latency origin of replication. Gray box I indicates the location of the glucocorticoid response element. Box II indicates the location of the Cp EBNA2-responsive enhancer. Box III indicates the location of the shared Cp-Wp enhancer. The C1, C2, W0, W1, and W2 exons are shown as black boxes. The bottom diagram represents the targeting plasmid used to incorporate the Cp EBNA2-responsive enhancer deletion into the viral genome. Cp*, tagged Cp in which the C1 exon contains a nucleotide sequence tag as previously described (23).
FIG. 2
FIG. 2
PhosphorImager analysis of a dot blot measuring the quantity of viral DNA in viral stocks. B95.8, mB95, and mE2mut stocks (1, 2, 10, and 20 μl) were lysed, blotted onto a nitrocellulose membrane, and hybridized with a probe specific for oriP. Relative signal quantitation is indicated in parentheses.
FIG. 3
FIG. 3
B-cell immortalization determining the transformation titer of viral stocks. Viral stocks at 100 (■), 10 (□), 1 (●), or 0.1 μl (○) were used to infect 3 × 106 primary B cells for 2 h. Cells were then plated in 96-well plates and examined for LCL formation over a period of 10 weeks. LCL-positive wells were scored on a weekly basis. p.i., postinfection.
FIG. 4
FIG. 4
S1 nuclease protection analysis of promoter activity at early times after infection with viral stocks. Peripheral blood lymphocytes were infected with mB95 or mE2mut virus, and cells were harvested for RNA at 24, 72, and 122 h postinfection. RNA (10 μg) was probed for Cp- and Wp-initiated transcripts. pos. cntl., positive control. (A) Representative experiment. (B) Summary of four experiments. Error bars indicate standard deviations.
FIG. 5
FIG. 5
S1 nuclease protection assay of er/eb 2-5 cells incubated with various concentrations of β-estradiol for 48 h. RNA was harvested and probed for Cp- and Wp-initiated transcription. Undigested probe is in the left lane of each panel. β-estradiol concentrations, from left to right, were 1, 0.1, 0.01, and 0 μM, respectively. (A) Actual S1 nuclease assay autoradiograph. (B) PhosphorImager quantitation of data from panel A.

Similar articles

Cited by

References

    1. Alfieri C, Birkenbach M, Kieff E. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology. 1991;181:595–608. . (Erratum, 185:946.) - PubMed
    1. Ben Sasson S A, Klein G. Activation of the Epstein-Barr virus genome by 5-aza-cytidine in latently infected human lymphoid lines. Int J Cancer. 1981;28:131–135. - PubMed
    1. Chang R S, Lung M L. A modified procedure for the propagation of wild-type Epstein-Barr virus in cultures of marmoset blood cells. J Virol Methods. 1994;46:167–178. - PubMed
    1. Cohen J I, Wang F, Mannick J, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA. 1989;86:9558–9562. - PMC - PubMed
    1. Desgranges C, Lenoir G, de The G, Seigneurin J M, Hilgers J, Dubouch P. In vitro transforming activity of EBV. I. Establishment and properties of two EBV strains (M81 and M72) produced by immortalized Callithrix jacchus lymphocytes. Biomedicine. 1976;25:349–352. - PubMed

Publication types

Substances